Michael Binks MD

Michael Binks joined Pfizer in 2014 to lead Clinical Research within the Rare Diseases Research Unit. I am currently the research project leader for the DMD gene therapy program. I qualified in medicine at University College London (UCL), UK before training in internal medicine, gastroenterology, neurology, respiratory and emergency medicine, and rheumatology.

Michael Binks UK accredited Rheumatologist. My scientific interests have been in immunology and immunopharmacology. I served as a Lecturer in Immunology and as an Arthritis Research Council and Jules Thorn Clinical Fellow at UCL, conducting research on antigen presentation and dendritic cell biology including the rare diseases Wiskott Aldrich Syndrome and scleroderma. Michael Binks joined the pharmaceutical industry in immune-inflammation discovery biology, translational and experimental medicine, and clinical pharmacology and has progressed programs from discovery to the clinic to POC.